Retrospective evaluation of bone pain palliation after samarium-153-EDTMP therapy
Autor(a) principal: | |
---|---|
Data de Publicação: | 2004 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Revista do Hospital das Clínicas |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0041-87812004000600003 |
Resumo: | PURPOSE: The aim of this study was to evaluate the degree of metastatic bone pain palliation and medullar toxicity associated with samarium-153-EDTMP treatment. METHODS: Seventy-three patients with metastatic bone pain having previously undergone therapy with samarium-153-EDTMP (1 mCi/kg) were retrospectively evaluated. Routine follow-up included pain evaluation and blood counts for 2 months after treatment. Pain was evaluated using a subjective scale (from 0 to 10) before and for 8 weeks after the treatment. Blood counts were obtained before treatment and once a week for 2 months during follow-up. Dosimetry, based upon the urinary excretion of the isotope, was estimated in 41 individuals, and the resulting radiation absorbed doses were correlated with hematological data. RESULTS: Reduction in pain scores of 75% to 100% was obtained in 36 patients (49%), with a decrease of 50% to 75%, 25% to 50%, and 0% to 25% in, respectively, 20 (27%), 10 (14%), and 7 (10%) patients. There was no significant relationship between the pain response and location of the primary tumor (breast or prostate cancer). Mild to moderate myelosuppression was noted in 75.3% of patients, usually with hematological recovery at 8 weeks. The mean bone marrow dose was 347 ± 65 cGy, and only a weak correlation was found between absorbed dose and myelosuppression (Pearson coefficient = .4). CONCLUSIONS: Samarium-153-EDTMP is a valuable method for metastatic bone pain palliation. A mild to moderate and transitory myelosuppression is the main toxicity observed after samarium therapy, showing a weak correlation with dosimetric measures. |
id |
USP-57_2afeb035e7e2a975587bac004e1652f1 |
---|---|
oai_identifier_str |
oai:scielo:S0041-87812004000600003 |
network_acronym_str |
USP-57 |
network_name_str |
Revista do Hospital das Clínicas |
repository_id_str |
|
spelling |
Retrospective evaluation of bone pain palliation after samarium-153-EDTMP therapySamariumPainScintigraphyPalliativeCareNeoplasmMetastasisPURPOSE: The aim of this study was to evaluate the degree of metastatic bone pain palliation and medullar toxicity associated with samarium-153-EDTMP treatment. METHODS: Seventy-three patients with metastatic bone pain having previously undergone therapy with samarium-153-EDTMP (1 mCi/kg) were retrospectively evaluated. Routine follow-up included pain evaluation and blood counts for 2 months after treatment. Pain was evaluated using a subjective scale (from 0 to 10) before and for 8 weeks after the treatment. Blood counts were obtained before treatment and once a week for 2 months during follow-up. Dosimetry, based upon the urinary excretion of the isotope, was estimated in 41 individuals, and the resulting radiation absorbed doses were correlated with hematological data. RESULTS: Reduction in pain scores of 75% to 100% was obtained in 36 patients (49%), with a decrease of 50% to 75%, 25% to 50%, and 0% to 25% in, respectively, 20 (27%), 10 (14%), and 7 (10%) patients. There was no significant relationship between the pain response and location of the primary tumor (breast or prostate cancer). Mild to moderate myelosuppression was noted in 75.3% of patients, usually with hematological recovery at 8 weeks. The mean bone marrow dose was 347 ± 65 cGy, and only a weak correlation was found between absorbed dose and myelosuppression (Pearson coefficient = .4). CONCLUSIONS: Samarium-153-EDTMP is a valuable method for metastatic bone pain palliation. A mild to moderate and transitory myelosuppression is the main toxicity observed after samarium therapy, showing a weak correlation with dosimetric measures.Faculdade de Medicina / Universidade de São Paulo - FM/USP2004-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0041-87812004000600003Revista do Hospital das Clínicas v.59 n.6 2004reponame:Revista do Hospital das Clínicasinstname:Universidade de São Paulo (USP)instacron:USP10.1590/S0041-87812004000600003info:eu-repo/semantics/openAccessSapienza,Marcelo TatitOno,Carla RachelGuimarães,Maria Inês CuryWatanabe,TomocoCosta,Paulo AguirreBuchpiguel,Carlos Albertoeng2005-02-10T00:00:00Zoai:scielo:S0041-87812004000600003Revistahttp://www.scielo.br/rhcPUBhttps://old.scielo.br/oai/scielo-oai.php||revista.hc@hcnet.usp.br1678-99030041-8781opendoar:2005-02-10T00:00Revista do Hospital das Clínicas - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
Retrospective evaluation of bone pain palliation after samarium-153-EDTMP therapy |
title |
Retrospective evaluation of bone pain palliation after samarium-153-EDTMP therapy |
spellingShingle |
Retrospective evaluation of bone pain palliation after samarium-153-EDTMP therapy Sapienza,Marcelo Tatit Samarium Pain Scintigraphy Palliative Care Neoplasm Metastasis |
title_short |
Retrospective evaluation of bone pain palliation after samarium-153-EDTMP therapy |
title_full |
Retrospective evaluation of bone pain palliation after samarium-153-EDTMP therapy |
title_fullStr |
Retrospective evaluation of bone pain palliation after samarium-153-EDTMP therapy |
title_full_unstemmed |
Retrospective evaluation of bone pain palliation after samarium-153-EDTMP therapy |
title_sort |
Retrospective evaluation of bone pain palliation after samarium-153-EDTMP therapy |
author |
Sapienza,Marcelo Tatit |
author_facet |
Sapienza,Marcelo Tatit Ono,Carla Rachel Guimarães,Maria Inês Cury Watanabe,Tomoco Costa,Paulo Aguirre Buchpiguel,Carlos Alberto |
author_role |
author |
author2 |
Ono,Carla Rachel Guimarães,Maria Inês Cury Watanabe,Tomoco Costa,Paulo Aguirre Buchpiguel,Carlos Alberto |
author2_role |
author author author author author |
dc.contributor.author.fl_str_mv |
Sapienza,Marcelo Tatit Ono,Carla Rachel Guimarães,Maria Inês Cury Watanabe,Tomoco Costa,Paulo Aguirre Buchpiguel,Carlos Alberto |
dc.subject.por.fl_str_mv |
Samarium Pain Scintigraphy Palliative Care Neoplasm Metastasis |
topic |
Samarium Pain Scintigraphy Palliative Care Neoplasm Metastasis |
description |
PURPOSE: The aim of this study was to evaluate the degree of metastatic bone pain palliation and medullar toxicity associated with samarium-153-EDTMP treatment. METHODS: Seventy-three patients with metastatic bone pain having previously undergone therapy with samarium-153-EDTMP (1 mCi/kg) were retrospectively evaluated. Routine follow-up included pain evaluation and blood counts for 2 months after treatment. Pain was evaluated using a subjective scale (from 0 to 10) before and for 8 weeks after the treatment. Blood counts were obtained before treatment and once a week for 2 months during follow-up. Dosimetry, based upon the urinary excretion of the isotope, was estimated in 41 individuals, and the resulting radiation absorbed doses were correlated with hematological data. RESULTS: Reduction in pain scores of 75% to 100% was obtained in 36 patients (49%), with a decrease of 50% to 75%, 25% to 50%, and 0% to 25% in, respectively, 20 (27%), 10 (14%), and 7 (10%) patients. There was no significant relationship between the pain response and location of the primary tumor (breast or prostate cancer). Mild to moderate myelosuppression was noted in 75.3% of patients, usually with hematological recovery at 8 weeks. The mean bone marrow dose was 347 ± 65 cGy, and only a weak correlation was found between absorbed dose and myelosuppression (Pearson coefficient = .4). CONCLUSIONS: Samarium-153-EDTMP is a valuable method for metastatic bone pain palliation. A mild to moderate and transitory myelosuppression is the main toxicity observed after samarium therapy, showing a weak correlation with dosimetric measures. |
publishDate |
2004 |
dc.date.none.fl_str_mv |
2004-01-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0041-87812004000600003 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0041-87812004000600003 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/S0041-87812004000600003 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Faculdade de Medicina / Universidade de São Paulo - FM/USP |
publisher.none.fl_str_mv |
Faculdade de Medicina / Universidade de São Paulo - FM/USP |
dc.source.none.fl_str_mv |
Revista do Hospital das Clínicas v.59 n.6 2004 reponame:Revista do Hospital das Clínicas instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Revista do Hospital das Clínicas |
collection |
Revista do Hospital das Clínicas |
repository.name.fl_str_mv |
Revista do Hospital das Clínicas - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
||revista.hc@hcnet.usp.br |
_version_ |
1754820894847401984 |